Invion Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVIXF research report →
About the company
Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as those found in the lung, prostate, ovaries, and in cases of mesothelioma. The company engages in strategic collaborations to further its research and development efforts.
- CEO
- Thian Chew
- IPO
- 2013
- Employees
- 4
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $4.03M
- P/E
- -0.24
- P/S
- 0.00
- P/B
- 0.48
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -150.48%
- ROIC
- -106.56%
- Revenue
- $0 · -100.00%
- Net Income
- $-5,796,848 · -3.00%
- EPS
- $-0.08 · -37.84%
- Op Income
- $-3,479,287
- FCF YoY
- 21.87%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.04
- 200D MA
- $0.04
- Beta
- 0.40
- Avg Volume
- 1.296
Get TickerSpark's AI analysis on IVIXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IVIXF coverage
Recent articles, reports, and earnings notes.
No research on IVIXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IVIXF report →Similar companies
Peers in the same neighborhood.